Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Agent for treating keratoconjunctival trouble

A technology of therapeutic agent and conjunctiva, applied in sensory diseases, aerosol delivery, drug combination and other directions, can solve the problem of no research reports on the pharmacological effects of eye diseases, etc., and achieve excellent effects and improve effects.

Inactive Publication Date: 2007-05-02
SANTEN PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there is no research report on the pharmacological effects of the above-mentioned compounds on eye diseases such as keratoconjunctivopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for treating keratoconjunctival trouble
  • Agent for treating keratoconjunctival trouble

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] The results of pharmacological tests and preparation examples are given below, and these examples are used to better understand the present invention, but not to limit the scope of the present invention.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

An object of the present invention is to search a new medicinal use of 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione and 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione. 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione or a salt thereof exerts an excellent improving effect on corneal disorder models, therefore, it is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis or conjunctivitis.

Description

technical field [0001] The present invention relates to containing thiazolidinedione derivative 5-[to-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione, 5-[[4 Dry eye, corneal ulcer, keratitis, A therapeutic agent for keratoconjunctivopathy such as conjunctivitis. Background technique [0002] It is known that the cornea is a transparent avascular tissue with a diameter of about 1 cm and a thickness of about 1 mm. The conjunctiva is the mucous membrane that covers the surface of the eyeball behind the limbus and the inside of the eyelids. The cornea or conjunctiva has an important impact on visual function. If corneal ulcer, keratitis, conjunctivitis, dry eye and other diseases cause keratoconjunctival lesions to be repaired delayed for some reason or protracted without repair, the cornea and conjunctiva are connected tissues, which will damage the epithelium. Normal structures are adversely affected and damage the structure or function of the corneal parenchy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D417/12A61K9/06A61K9/08A61K31/4439A61P27/02A61P27/04A61P27/14A61K9/00
CPCA61K9/0048A61K31/4439A61P27/02A61P27/04A61P27/14C07D417/12
Inventor 中村雅胤平井慎一郎
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com